Category: Latest

Two drugs under review by the FDA—dabrafenib and trametinib—seem to slow development of treatment resistance in patients with metastatic malignant melanoma. http://www.pharmacytimes.com/news/Combatting-Treatment-Resistance-in-Metastatic-Melanoma-Therapy

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed venenatis facilisis nulla quis tempor. Nulla sem metus, convallis eget feugiat in, congue aliquam leo. Nulla facilisi. Etiam viverra luctus nulla, in venenatis ante auctor sit amet. Phasellus in lacus orci. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Ut in enim…